Compare Stocks: BPTH, SNOA, NCNA, and ENVB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTH Bio-Path	$0.03	$0.04	$0.01 ▼ $0.13	$1.40M	-0.51	25,673 shs	2,588 shs
ENVB Enveric Biosciences	$1.37	$1.42	$1.17 ▼ $15.12	$6.13M	1.13	144,931 shs	38,280 shs
NCNA NuCana	$1.47 -16.5%	$1.42	$1.21 ▼ $7.22	$7.33M	2.25	83,556 shs	192,823 shs
SNOA Sonoma Pharmaceuticals	$1.29 -1.5%	$1.24	$0.85 ▼ $4.77	$6.27M	1.28	243,486 shs	95,836 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTH Bio-Path	0.00%	-23.53%	-31.58%	-37.35%	-75.95%
ENVB Enveric Biosciences	0.00%	-4.20%	-12.74%	-39.38%	-89.90%
NCNA NuCana	0.00%	+15.79%	+33.33%	-18.89%	-44.83%
SNOA Sonoma Pharmaceuticals	0.00%	-2.24%	+19.09%	+10.55%	-70.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPTH Bio-Path	$0.03	$0.04	$0.01 ▼ $0.13	$1.40M	-0.51	25,673 shs	2,588 shs
ENVB Enveric Biosciences	$1.37	$1.42	$1.17 ▼ $15.12	$6.13M	1.13	144,931 shs	38,280 shs
NCNA NuCana	$1.47 -16.5%	$1.42	$1.21 ▼ $7.22	$7.33M	2.25	83,556 shs	192,823 shs
SNOA Sonoma Pharmaceuticals	$1.29 -1.5%	$1.24	$0.85 ▼ $4.77	$6.27M	1.28	243,486 shs	95,836 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPTH Bio-Path	0.00%	-23.53%	-31.58%	-37.35%	-75.95%
ENVB Enveric Biosciences	0.00%	-4.20%	-12.74%	-39.38%	-89.90%
NCNA NuCana	0.00%	+15.79%	+33.33%	-18.89%	-44.83%
SNOA Sonoma Pharmaceuticals	0.00%	-2.24%	+19.09%	+10.55%	-70.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPTH Bio-Path	0.00	N/A	N/A	N/A
ENVB Enveric Biosciences	1.00	Sell	N/A	N/A
NCNA NuCana	1.00	Sell	N/A	N/A
SNOA Sonoma Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BPTH, SNOA, NCNA, and ENVB Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/21/2026	SNOA Sonoma Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	SNOA Sonoma Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	SNOA Sonoma Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	ENVB Enveric Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	NCNA NuCana	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPTH Bio-Path	N/A	N/A	N/A	N/A	$0.71 per share	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$7.00 per share	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	$7.71 per share	N/A
SNOA Sonoma Pharmaceuticals	$19.53M	0.32	N/A	N/A	$0.65 per share	1.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPTH Bio-Path	-$16.08M	-$1.09	N/A	N/A	N/A	N/A	-2,842.40%	-337.48%	11/12/2026 (Estimated)
ENVB Enveric Biosciences	-$8.77M	-$12.65	N/A	N/A	N/A	N/A	-168.04%	-145.95%	11/12/2026 (Estimated)
NCNA NuCana	-$38.71M	-$3.81	N/A	N/A	N/A	N/A	-41.90%	-33.69%	11/12/2026 (Estimated)
SNOA Sonoma Pharmaceuticals	-$3.17M	-$1.22	N/A	N/A	N/A	-10.33%	-21.41%	-6.08%	11/16/2026 (Estimated)

Latest BPTH, SNOA, NCNA, and ENVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ENVB Enveric Biosciences	N/A	-$0.76	N/A	-$0.76	N/A	N/A
8/13/2026	Q2 2026	NCNA NuCana	-$2.6514	-$0.99	+$1.6614	N/A	N/A	N/A
8/6/2026	Q1 2027	SNOA Sonoma Pharmaceuticals	-$0.30	$0.02	+$0.32	-$0.09	$4.99 million	$6.41 million
6/16/2026	Q4 2026	SNOA Sonoma Pharmaceuticals	-$0.24	-$0.33	-$0.09	-$0.33	$5.57 million	$5.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPTH Bio-Path	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
SNOA Sonoma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPTH Bio-Path	N/A	0.86	0.86
ENVB Enveric Biosciences	N/A	10.21	10.21
NCNA NuCana	N/A	4.73	4.73
SNOA Sonoma Pharmaceuticals	N/A	2.99	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPTH Bio-Path	5.74%
ENVB Enveric Biosciences	13.82%
NCNA NuCana	44.00%
SNOA Sonoma Pharmaceuticals	1.95%

Insider Ownership

Company	Insider Ownership
BPTH Bio-Path	0.72%
ENVB Enveric Biosciences	2.41%
NCNA NuCana	31.20%
SNOA Sonoma Pharmaceuticals	1.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPTH Bio-Path	10	53.90 million	5.73 million	No Data
ENVB Enveric Biosciences	20	4.48 million	4.37 million	Not Optionable
NCNA NuCana	30	4.16 million	2.86 million	Not Optionable
SNOA Sonoma Pharmaceuticals	180	4.79 million	4.74 million	Not Optionable

BPTH, SNOA, NCNA, and ENVB Headlines

Recent News About These Companies

Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting

August 19, 2026 | tipranks.com

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

August 6, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

August 6, 2026 | benzinga.com

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

June 30, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity

June 18, 2026 | tipranks.com

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

June 16, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

June 16, 2026 | accessnewswire.comA

What's going on with Sonoma Pharma stock Monday?

April 27, 2026 | msn.com

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

April 25, 2026 | finance.yahoo.com

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

March 24, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

March 24, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey’s Aquanil Brand for Sensitive Skin

March 18, 2026 | freep.comF

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin

March 18, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

February 10, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

February 10, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

January 29, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

January 28, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

November 14, 2025 | finanznachrichten.de

Sonoma Pharmaceuticals’ Reliefacyn Advanced receives NRS Seal of Acceptance

November 13, 2025 | msn.com

National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

November 13, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH, SNOA, NCNA, and ENVB Company Descriptions

Bio-Path NASDAQ:BPTH

$0.03 0.00 (0.00%)

As of 02:23 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Enveric Biosciences NASDAQ:ENVB

$1.37 0.00 (0.00%)

As of 04:00 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

NuCana NASDAQ:NCNA

$1.47 -0.29 (-16.48%)

As of 04:00 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.29 -0.02 (-1.53%)

As of 04:00 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPTH, SNOA, NCNA, and ENVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPTH, SNOA, NCNA, and ENVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPTH, SNOA, NCNA, and ENVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH, SNOA, NCNA, and ENVB Company Descriptions

Bio-Path NASDAQ:BPTH

Enveric Biosciences NASDAQ:ENVB

NuCana NASDAQ:NCNA

Sonoma Pharmaceuticals NASDAQ:SNOA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPTH, SNOA, NCNA, and ENVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPTH, SNOA, NCNA, and ENVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPTH, SNOA, NCNA, and ENVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH, SNOA, NCNA, and ENVB Company Descriptions

Bio-Path NASDAQ:BPTH

Enveric Biosciences NASDAQ:ENVB

NuCana NASDAQ:NCNA

Sonoma Pharmaceuticals NASDAQ:SNOA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools